Media

July 6, 2022 | Publication
A lymph node targeted CpG, TLR9 agonist induces potent activation of lymphaticinnate immune responses resulting in robust cellular and humoral immunity to SARS-CoV-2
Scientific Poster
July 6, 2022 | Publication
A Lymph Node Targeted Protein Subunit Vaccine Induces Robust Cellular and Humoral Immunity to SARS-CoV-2 in Non-human Primates
Scientific Poster
July 6, 2022 | Publication
A lymph node targeted protein subunit vaccine generates strong cellular and crossreactive humoral immunity against SARS-CoV-2 with potent long-term recall responses
Scientific Poster
July 6, 2022 | Publication
A Lymph Node Targeted Engineered Subunit Antigen and Molecular Adjuvant Vaccine Promotes Potent Cellular and Humoral Immunity to Epstein Barr Virus in HLA expressing Mice
Scientific Poster
June 6, 2022 | Publication
TPS2701: First in human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten Rat Sarcoma (KRAS) mutated pancreatic ductal adenocarcinoma and other solid tumors (trial in progress)
Scientific Poster
June 4, 2022 | In the News
Developing Subunit Vaccines Based on an Amphiphile Platform
BIOPROCESS INTERNATIONAL: Subunit vaccines stimulate immune cells by delivering selected components of a pathogen of interest rather than the entire pathogen. Elicio Therapeutics is developing subunit vaccines that target a recipient’s lymph node to elicit a robust immune response.
May 23, 2022 | In the News
Elicio Touts “Huge Potential” for Cancer Vaccine Following Preclinical Data
BIOSPACE: Immuno-oncology has grown enormously in the last decade, and the COVID-19 pandemic has accelerated our knowledge of the immune system. Elicio Therapeutics published data on the preprint server, bioRxiv, describing preclinical research on its cancer vaccine that shows a lot of promise.
May 17, 2022 | In the News
Elicio inks deal with Regeneron to evaluate ELI-002 in combination with Libtay
THE PHARMA LETTER: USA-based clinical-stage biotech Elicio Therapeutics has entered into a clinical supply agreement with Regeneron Pharmaceuticals (Nasdaq: REGN) to evaluate the safety and efficacy of Elicio’s lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in combination with Regeneron’s Libtayo (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in patients with KRAS-driven tumors.
May 13, 2022 | In the News
BioSpace Movers & Shakers: Singular Genomics, Marengo, Ventyx, Caribou and More
BIOSPACE: Building stronger companies requires the right leadership. This week, life sciences companies from across the globe pinpoint the Movers & Shakers who will best benefit their company.
May 5, 2022 | Publication
Lymph node-targeted vaccine boosting of TCR-T cell therapy enhances anti-tumor function and eradicates solid tumors
BioRxIV, Drakes, et. al.